Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

STING promotes homeostasis via regulation of cell proliferation and chromosomal stability.

Ranoa DRE, Widau RC, Mallon S, Parekh AD, Nicolae CM, Huang X, Bolt MJ, Arina A, Parry R, Kron SJ, Moldovan GL, Khodarev NN, Weichselbaum RR.

Cancer Res. 2018 Nov 27. pii: canres.1972.2018. doi: 10.1158/0008-5472.CAN-18-1972. [Epub ahead of print]

PMID:
30482772
2.

Non-canonical NF-κB Antagonizes STING Sensor-Mediated DNA Sensing in Radiotherapy.

Hou Y, Liang H, Rao E, Zheng W, Huang X, Deng L, Zhang Y, Yu X, Xu M, Mauceri H, Arina A, Weichselbaum RR, Fu YX.

Immunity. 2018 Sep 18;49(3):490-503.e4. doi: 10.1016/j.immuni.2018.07.008. Epub 2018 Aug 28.

PMID:
30170810
3.

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ.

J Clin Oncol. 2018 Jun 1;36(16):1611-1618. doi: 10.1200/JCO.2017.76.2229. Epub 2018 Feb 13.

PMID:
29437535
4.

Tumour ischaemia by interferon-γ resembles physiological blood vessel regression.

Kammertoens T, Friese C, Arina A, Idel C, Briesemeister D, Rothe M, Ivanov A, Szymborska A, Patone G, Kunz S, Sommermeyer D, Engels B, Leisegang M, Textor A, Fehling HJ, Fruttiger M, Lohoff M, Herrmann A, Yu H, Weichselbaum R, Uckert W, Hübner N, Gerhardt H, Beule D, Schreiber H, Blankenstein T.

Nature. 2017 May 4;545(7652):98-102. doi: 10.1038/nature22311. Epub 2017 Apr 26.

5.

Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.

Arina A, Karrison T, Galka E, Schreiber K, Weichselbaum RR, Schreiber H.

Cancer Immunol Res. 2017 Feb;5(2):127-136. doi: 10.1158/2326-6066.CIR-16-0293. Epub 2017 Jan 11.

6.

Tumor relapse prevented by combining adoptive T cell therapy with Salmonella typhimurium.

Binder DC, Arina A, Wen F, Tu T, Zhao M, Hoffman RM, Wainwright DA, Schreiber H.

Oncoimmunology. 2016 Feb 18;5(6):e1130207. doi: 10.1080/2162402X.2015.1130207. eCollection 2016 Jun.

7.

Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance.

Zheng W, Skowron KB, Namm JP, Burnette B, Fernandez C, Arina A, Liang H, Spiotto MT, Posner MC, Fu YX, Weichselbaum RR.

Oncotarget. 2016 Jul 12;7(28):43039-43051. doi: 10.18632/oncotarget.9915.

8.

Tumor-associated fibroblasts predominantly come from local and not circulating precursors.

Arina A, Idel C, Hyjek EM, Alegre ML, Wang Y, Bindokas VP, Weichselbaum RR, Schreiber H.

Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):7551-6. doi: 10.1073/pnas.1600363113. Epub 2016 Jun 17.

9.

Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment.

Arina A, Corrales L, Bronte V.

Semin Immunol. 2016 Feb;28(1):54-63. doi: 10.1016/j.smim.2016.01.002. Epub 2016 Feb 10. Review.

PMID:
26872631
10.

Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation.

Leisegang M, Engels B, Schreiber K, Yew PY, Kiyotani K, Idel C, Arina A, Duraiswamy J, Weichselbaum RR, Uckert W, Nakamura Y, Schreiber H.

Clin Cancer Res. 2016 Jun 1;22(11):2734-43. doi: 10.1158/1078-0432.CCR-15-2361. Epub 2015 Dec 14.

11.

Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells.

Arina A, Bronte V.

Curr Opin Immunol. 2015 Apr;33:120-5. doi: 10.1016/j.coi.2015.02.006. Epub 2015 Feb 27. Review.

PMID:
25728992
12.

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.

Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, Huang X, Gajewski TF, Chen ZJ, Fu YX, Weichselbaum RR.

Immunity. 2014 Nov 20;41(5):843-52. doi: 10.1016/j.immuni.2014.10.019. Epub 2014 Nov 6.

13.
14.

Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer.

Schietinger A, Arina A, Liu RB, Wells S, Huang J, Engels B, Bindokas V, Bartkowiak T, Lee D, Herrmann A, Piston DW, Pittet MJ, Lin PC, Zal T, Schreiber H.

Oncoimmunology. 2013 Nov 1;2(11):e26677. Epub 2013 Nov 4.

15.

Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.

Binder DC, Engels B, Arina A, Yu P, Slauch JM, Fu YX, Karrison T, Burnette B, Idel C, Zhao M, Hoffman RM, Munn DH, Rowley DA, Schreiber H.

Cancer Immunol Res. 2013 Aug;1(2):123-33. doi: 10.1158/2326-6066.CIR-13-0058.

16.

Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression.

Arina A, Schreiber K, Binder DC, Karrison TG, Liu RB, Schreiber H.

J Immunol. 2014 Feb 1;192(3):1286-93. doi: 10.4049/jimmunol.1202498. Epub 2013 Dec 23.

17.

Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapy.

Ochoa MC, Fioravanti J, Duitman EH, Medina-Echeverz J, Palazon A, Arina A, Dubrot J, Alfaro C, Morales-Kastresana A, Murillo O, Hervas-Stubbs S, Prieto J, Berraondo P, Melero I.

PLoS One. 2012;7(12):e52370. doi: 10.1371/journal.pone.0052370. Epub 2012 Dec 21.

18.

Spleen cells from young but not old immunized mice eradicate large established cancers.

Schreiber K, Arina A, Engels B, Spiotto MT, Sidney J, Sette A, Karrison TG, Weichselbaum RR, Rowley DA, Schreiber H.

Clin Cancer Res. 2012 May 1;18(9):2526-33. doi: 10.1158/1078-0432.CCR-12-0127. Epub 2012 Mar 13.

19.

Densely granulated murine NK cells eradicate large solid tumors.

Liu RB, Engels B, Arina A, Schreiber K, Hyjek E, Schietinger A, Binder DC, Butz E, Krausz T, Rowley DA, Jabri B, Schreiber H.

Cancer Res. 2012 Apr 15;72(8):1964-74. doi: 10.1158/0008-5472.CAN-11-3208. Epub 2012 Feb 28.

20.

Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genes.

Wu TH, Schreiber K, Arina A, Khodarev NN, Efimova EV, Rowley DA, Weichselbaum RR, Schreiber H.

Cancer Immun. 2011 Jun 30;11:2.

21.

Proliferating NK cells in response to IL-15 do not upregulate surface B220 in vivo.

Murillo O, Ochoa MC, Arina A, Gabari I, Dubrot J, Hervas-Stubbs S, Melero I.

Gene Ther. 2010 May;17(5):687-9. doi: 10.1038/gt.2009.139. Epub 2009 Oct 29. No abstract available.

PMID:
19865177
22.

In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb.

Murillo O, Dubrot J, Palazón A, Arina A, Azpilikueta A, Alfaro C, Solano S, Ochoa MC, Berasain C, Gabari I, Pérez-Gracia JL, Berraondo P, Hervás-Stubbs S, Melero I.

Eur J Immunol. 2009 Sep;39(9):2424-36. doi: 10.1002/eji.200838958.

23.

Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma.

Murillo O, Arina A, Hervas-Stubbs S, Gupta A, McCluskey B, Dubrot J, Palazón A, Azpilikueta A, Ochoa MC, Alfaro C, Solano S, Pérez-Gracia JL, Oyajobi BO, Melero I.

Clin Cancer Res. 2008 Nov 1;14(21):6895-906. doi: 10.1158/1078-0432.CCR-08-0285.

24.

Interleukin-15 liver gene transfer increases the number and function of IKDCs and NK cells.

Arina A, Murillo O, Dubrot J, Azpilikueta A, Gabari I, Perez-Gracia JL, Alfaro C, Berasain C, Prieto J, Ferrini S, Hervas-Stubbs S, Melero I.

Gene Ther. 2008 Apr;15(7):473-83. doi: 10.1038/gt.2008.4. Epub 2008 Feb 14.

PMID:
18273053
25.

Immunotherapy and immunoescape in colorectal cancer.

Mazzolini G, Murillo O, Atorrasagasti C, Dubrot J, Tirapu I, Rizzo M, Arina A, Alfaro C, Azpilicueta A, Berasain C, Perez-Gracia JL, Gonzalez A, Melero I.

World J Gastroenterol. 2007 Nov 28;13(44):5822-31. Review.

26.

Bone-marrow-derived cell differentiation into microglia: a study in a progressive mouse model of Parkinson's disease.

Rodriguez M, Alvarez-Erviti L, Blesa FJ, Rodríguez-Oroz MC, Arina A, Melero I, Ramos LI, Obeso JA.

Neurobiol Dis. 2007 Dec;28(3):316-25. Epub 2007 Aug 7.

PMID:
17897835
27.

The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN gamma.

Arina A, Murillo O, Hervás-Stubbs S, Azpilikueta A, Dubrot J, Tirapu I, Huarte E, Alfaro C, Pérez-Gracia JL, González-Aseguinolaza G, Sarobe P, Lasarte JJ, Jamieson A, Prieto J, Raulet DH, Melero I.

Int J Cancer. 2007 Sep 15;121(6):1282-95.

28.

Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer.

Arina A, Murillo O, Dubrot J, Azpilikueta A, Alfaro C, Pérez-Gracia JL, Bendandi M, Palencia B, Hervás-Stubbs S, Melero I.

Expert Opin Biol Ther. 2007 May;7(5):599-615. Review.

29.

[The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].

Alfaro C, Murillo O, Tirapu I, Azpilicueta A, Huarte E, Arina A, Arribillaga L, Pérez-Gracia JL, Bendandi M, Prieto J, Lasarte JJ, Melero I.

An Sist Sanit Navar. 2006 Jan-Apr;29(1):77-96. Review. Spanish.

30.

Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena.

Melero I, Arina A, Murillo O, Dubrot J, Alfaro C, Pérez-Gracia JL, Bendandi M, Hervás-Stubbs S.

Clin Cancer Res. 2006 Apr 15;12(8):2385-9. No abstract available.

31.

Recombinant adenoviral vectors turn on the type I interferon system without inhibition of transgene expression and viral replication.

Huarte E, Larrea E, Hernández-Alcoceba R, Alfaro C, Murillo O, Arina A, Tirapu I, Azpilicueta A, Hervás-Stubbs S, Bortolanza S, Pérez-Gracia JL, Civeira MP, Prieto J, Riezu-Boj JI, Melero I.

Mol Ther. 2006 Jul;14(1):129-38. Epub 2006 Apr 19.

32.

Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma.

Tirapu I, Huarte E, Guiducci C, Arina A, Zaratiegui M, Murillo O, Gonzalez A, Berasain C, Berraondo P, Fortes P, Prieto J, Colombo MP, Chen L, Melero I.

Cancer Res. 2006 Feb 15;66(4):2442-50.

33.

The many sounds of T lymphocyte silence.

Melero I, Arina A, Chen L.

Immunol Res. 2005;33(2):135-47. Review.

34.

Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus.

Arribillaga L, Sarobe P, Arina A, Gorraiz M, Borrás-Cuesta F, Ruiz J, Prieto J, Chen L, Melero I, Lasarte JJ.

Vaccine. 2005 May 20;23(27):3493-9.

35.

Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8.

Feijoó E, Alfaro C, Mazzolini G, Serra P, Peñuelas I, Arina A, Huarte E, Tirapu I, Palencia B, Murillo O, Ruiz J, Sangro B, Richter JA, Prieto J, Melero I.

Int J Cancer. 2005 Aug 20;116(2):275-81.

36.

Intratumoural administration of dendritic cells: hostile environment and help by gene therapy.

Huarte E, Tirapu I, Arina A, Vera M, Alfaro C, Murillo O, Palencia B, Busto V, Marín V, Mazzolini G, Melero I.

Expert Opin Biol Ther. 2005 Jan;5(1):7-22. Review.

37.

Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas.

Mazzolini G, Alfaro C, Sangro B, Feijoó E, Ruiz J, Benito A, Tirapu I, Arina A, Sola J, Herraiz M, Lucena F, Olagüe C, Subtil J, Quiroga J, Herrero I, Sádaba B, Bendandi M, Qian C, Prieto J, Melero I.

J Clin Oncol. 2005 Feb 10;23(5):999-1010. Epub 2004 Dec 14.

38.

Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens.

Tirapu I, Arina A, Mazzolini G, Duarte M, Alfaro C, Feijoo E, Qian C, Chen L, Prieto J, Melero I.

Int J Cancer. 2004 May 20;110(1):51-60.

39.

Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies.

Murillo O, Arina A, Tirapu I, Alfaro C, Mazzolini G, Palencia B, López-Diaz De Cerio A, Prieto J, Bendandi M, Melero I.

Clin Cancer Res. 2003 Nov 15;9(15):5454-64. Review.

40.

Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses.

Sarobe P, Lasarte JJ, Zabaleta A, Arribillaga L, Arina A, Melero I, Borrás-Cuesta F, Prieto J.

J Virol. 2003 Oct;77(20):10862-71.

41.

Anti-ICAM-2 monoclonal antibody synergizes with intratumor gene transfer of interleukin-12 inhibiting activation-induced T-cell death.

Melero I, Gabari I, Tirapu I, Arina A, Mazzolini G, Baixeras E, Feijoo E, Alfaro C, Qian C, Prieto J.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3546-54.

42.

Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFNgamma-induced apoptosis.

Mazzolini G, Narvaiza I, Martinez-Cruz LA, Arina A, Barajas M, Galofré JC, Qian C, Mato JM, Prieto J, Melero I.

Gene Ther. 2003 Jul;10(13):1067-78.

43.

Clinical implications of antigen transfer mechanisms from malignant to dendritic cells. exploiting cross-priming.

Arina A, Tirapu I, Alfaro C, Rodríguez-Calvillo M, Mazzolini G, Inogés S, López A, Feijoo E, Bendandi M, Melero I.

Exp Hematol. 2002 Dec;30(12):1355-64. Review.

44.

Effective tumor immunotherapy: start the engine, release the brakes, step on the gas pedal,...and get ready to face autoimmunity.

Tirapu I, Mazzolini G, Rodriguez-Calvillo M, Arina A, Palencia B, Gabari I, Melero I.

Arch Immunol Ther Exp (Warsz). 2002;50(1):13-8. Review.

PMID:
11916305
45.

Expression of CD3 and CD11b antigens on blood and mammary gland leukocytes and bacterial survival in milk of cows with experimentally induced Staphylococcus aureus mastitis.

Rivas AL, Quimby FW, Coksaygan O, Alba A, Arina A, Arrobas MJ, González RN, Mohammed HO, Lein DH.

Am J Vet Res. 2001 Dec;62(12):1840-51.

PMID:
11763169

Supplemental Content

Support Center